Pasireotide for malignant insulinoma

Hormones

Volumn 15, Issue 2, 2016, Pages 271-276

  Tirosh, Amit ^a,b   Stemmer, Salomon M ^a,b   Solomonov, Evgeny ^c   Elnekave, Eldad ^a   Saeger, Wolfgang ^d   Ravkin, Yelena ^e   Nir, Kobi ^f   Talmor, Yeela ^a   Shimon, Ilan ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Rebecca Sieff Government Hospital   (Israel)

^d UNIVERSITY OF HAMBURG   (Germany)

^e CLALIT HEALTH SERVICES   (Israel)

^f Novartis Pharma   (Israel)

Author keywords

Hypoglycemia; Insulinoma; Neuroendocrine; Pasireotide

Indexed keywords

ANGIOPEPTIN; C PEPTIDE; CHROMOGRANIN A; EVEROLIMUS; GLUCOSE; INSULIN; KI 67 ANTIGEN; PASIREOTIDE; SYNAPTOPHYSIN; YTTRIUM 90; ANTINEOPLASTIC AGENT; SOMATOSTATIN;

ABDOMINAL PAIN; AGED; ANEMIA; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLOOD GLUCOSE MONITORING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; EPISTAXIS; FAINTNESS; FATIGUE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HUMAN TISSUE; HYPERINSULINISM; HYPERPHAGIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULINOMA; LIVER BIOPSY; LIVER METASTASIS; MALE; MALIGNANT INSULINOMA; MEDICAL HISTORY; MOUTH ULCER; NEUTROPENIA; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; RECURRENT DISEASE; SELECTIVE INTERNAL RADIATION THERAPY; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BIOPSY; BLOOD; CLASSIFICATION; COMPLICATION; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; LIVER RESECTION; LIVER TUMOR; METABOLISM; PANCREATECTOMY; PATHOLOGY; SECONDARY; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BIOPSY; BLOOD GLUCOSE; HEPATECTOMY; HUMANS; HYPOGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSULINOMA; LIVER NEOPLASMS; MALE; PANCREATECTOMY; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; SOMATOSTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84976478968     PISSN: 11093099     EISSN: 25208721     Source Type: Journal    
DOI: 10.14310/horm.2002.1639     Document Type: Article

References (10)

1. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G, 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146: 707-716.
2. Yao JC, Shah MH, Ito T, et al, 2011 Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514-523.
3. Kulke MH, Bergsland EK, Yao JC, 2009 Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 360: 195-197.
4. Kailey B, van de Bunt M, Cheley S, et al, 2012 SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells. Am J Physiol Endocrinol Metab 303: E1107-E1116.
5. Zambre Y, Ling Z, Chen MC, et al, 1999 Inhibition of human pancreatic islet insulin release by receptorselective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol 57: 1159-1164.
6. Colao A, Petersenn S, Newell-Price J, et al, 2012 A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 366: 914-924.
7. Gadelha MR, Bronstein MD, Brue T, et al, 2014 Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2: 875-884.
8. Henry RR, Ciaraldi TP, Armstrong D, et al, 2013 Hyperglycemia associated with pasireotide: Results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98: 3446-3453.
9. Hofland LJ, Lamberts SWJ, 2003 The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24: 28-47.
10. Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, Janson ET, 2007 Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4. Endocr Pathol 18: 79-85.